What are the new drugs for the treatment of hepatitis C?

Drugs.com

Official answer

by Drugs.com

The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir).

Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).

  • Mavyret is used to treat patients 3 years of age and older. Mavyret is also approved for patients 3 years and older with HCV genotype 1 infection, who have previously been treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
  • Vosevi is indicated for use in the treatment of adult patients. It is used as a re-treatment option in patients who have been previously treated with an NS5A inhibitor-containing regimen (GT1-6), or a regimen containing sofosbuvir without an NS5A inhibitor (GT1a or GT3).
  • Epclusa is approved for use in adults and children 3 years of age and older. Epclusa is also approved in adults and children 3 years of age and older for the treatment of HCV genotype 1, 2, 3, 4, 5 or 6 in patients with decompensated cirrhosis (for use in combination with ribavirin).

    • Latest FDA Approvals for Hepatitis C

    Drug Type Dosage Form Company Hepatitis C Indications Patient Population
    Mavyret (glecaprevir and pibrentasvir) FDA Approved 2017 glecaprevir NS3/4A protease inhibitor pibrentasvir NS5A inhibitor tablets, pellets (children 3 to less than 12 years old weighing less than 45 kg) AbbVie Inc. genotypes 1,2,3,4,5,6 adults and children 3 years of age and older
    Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) FDA Approved 2017 sofosbuvir nucleotide analog NS5B polymerase inhibitor velpatasvir NS5A inhibitor voxilaprevir NS3/4A protease inhibitor tablets Gilead Sciences, Inc. genotypes 1,2,3,4,5,6 adults
    Epclusa (sofosbuvir and velpatasvir) FDA Approved 2016 sofosbuvir nucleotide analog NS5B polymerase inhibitor velpatasvir NS5A inhibitor tablets; oral pellets (for children less than 6 years old) Gilead Sciences, Inc. genotypes 1,2,3,4,5,6 adults and children 3 years of age and older
    Zepatier (elbasvir and grazoprevir) FDA Approved 2016 elbasvir NS5A inhibitor grazoprevir NS3/4A protease inhibitor tablets Merck genotypes 1 or 4; is used with ribavirin in certain patient populations adults and children 12 years of age and older or weighing at least 66 lb (30 kg)
    Harvoni (ledipasvir and sofosbuvir) FDA Approved 2014 ledipasvir NS5A inhibitor sofosbuvir nucleotide analog NS5B polymerase inhibitor tablets and oral pellets Gilead Sciences, Inc. genotypes 1, 4, 5 or 6; is used with ribavirin in certain patient populations adults and children 3 years and older
    Sovaldi (sofosbuvir) FDA Approved 2013 sofosbuvir nucleotide analog NS5B polymerase inhibitor tablets and oral pellets Gilead Sciences, Inc. genotypes 1, 2, 3 or 4; must be given in combination with other antiviral medications (ribavirin; peginterferon alfa) adults (type 1-4) and children 3 years and older (type 2-3)
    Discontinued Products
    Viekira XR, Viekira Pak (dasabuvir, ombitasvir, paritaprevir, and ritonavir) FDA Approved 2016 (discontinued) dasabuvir non-nucleoside NS5B palm polymerase inhibitor ombitasvir NS5A inhibitor paritaprevir NS3/4A protease inhibitor ritonavir CYP3A inhibitor extended release tablets; tablets (co-packaged) AbbVie Inc. genotypes 1a or 1b adults
    Daklinza (daclatasvir)

    FDA Approved 2015 (discontinued)

    		 daclatasvir NS5A inhibitor tablets BMS genotypes 1 or 3 adults
    Technivie (ombitasvir, paritaprevir, and ritonavir)

    FDA Approved 2015 (discontinued)

    		 ombitasvir NS5A inhibitor paritaprevir NS3/4A protease inhibitor ritonavir CYP3A inhibitor tablets AbbVie Inc. genotype 4 adults
    Olysio (simeprevir)

    FDA Approved 2013 (discontinued)

    		 simeprevir NS3/4A protease inhibitor capsules Janssen Pharmaceuticals, Inc. genotypes 1 or 4 adults
    Incivek (telaprevir) FDA Approved 2011 (discontinued) telaprevir NS3/4A protease inhibitor tablets Vertex Pharmaceuticals Inc. genotype 1 adults
    Victrelis (boceprevir)

    FDA Approved 2011 (discontinued)

    		 boceprevir NS3/4A protease inhibitor capsules Merck genotype 1 adults

    For more information, see Oral Hepatitis C Treatments: The Evolving Landscape

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords